CERENIS SNAGS $30.5M
French pharmaceutical startup Cerenis Therapeutics said on Monday it has completed a €25-million ($30.5 million) first round of financing. The deal was co-led by Sofinnova Partners (France) and HealthCap (Sweden). Alta Partners (United States), EDF Ventures (U.S.), and NIF Ventures (Japan) also participated in the round. Toulouse-based Cerenis was incorporated in March 2005 to discover, develop, and commercialize high-density lipoprotein (HDL)-related therapies for the treatment of cardiovascular and metabolic diseases. HDL is also known as "good" cholesterol.